Laureat of a european H2020 project, Mensia receives 3.6M€

MENSIA Technologies receives €3.6 million from the EU to develop NEWROFEED, a non-invasive, non-drug solution for the treatment of ADHD in children (Attention Deficit with or without Hyperactivity Disorder).

The project aims at developping a Neurofeedback solution for ADHD children, used at home by patients aged from 7 to 14 years old, under medical prescription and supervision by ADHD specialists. A multicenter clinical trial will be launched in May 2016 in 10 european countries and finance will be provided by

See press release in english or french for further details